Novo Nordisk’s Next Act: Can CagriSema Reclaim GLP-1 Dominance?
Ozempic has been a major growth driver for Novo Nordisk (NYSE: NVO) for years, becoming a household name in the process. However, the Danish drugmaker has recently lost ground to Eli Lilly (NYSE: LLY) in the competitive GLP-1 market. Can Novo Nordisk regain its footing? The answer likely lies in its next-generation therapies, as current product sales are expected to decline this year, according to company guidance.
Introducing CagriSema: A Dual-Action Approach
One of Novo Nordisk’s most promising candidates is CagriSema. This investigational medicine has been gaining attention for its potential to outperform existing GLP-1 drugs. CagriSema is a dual agonist, mimicking the actions of both GLP-1 and amylin – gut hormones that regulate blood sugar and appetite.
Phase 3 Trial Results: CagriSema vs. Semaglutide
Late in 2024, Novo Nordisk announced positive results from a phase 3 weight-loss clinical trial. CagriSema demonstrated superior performance compared to semaglutide (Wegovy for weight loss and Ozempic for diabetes) in overweight or obese patients without type 2 diabetes. After 68 weeks, CagriSema led to a mean weight reduction of 22.7%, compared to 16.1% with Wegovy.
Patient self-administering shot.
CagriSema in Type 2 Diabetes: Another Victory
Novo Nordisk recently shared data from another late-stage study, this time comparing CagriSema to Ozempic in patients with type 2 diabetes who were also overweight or obese. CagriSema resulted in an average 1.91% reduction in blood sugar from baseline (8.2%) and an average weight loss of 14.2%. Again, CagriSema outperformed Ozempic in this trial.
What’s on the Horizon for Novo Nordisk?
Novo Nordisk has already submitted regulatory applications for CagriSema as a weight loss treatment and plans to seek approval for its use in diabetes after completing two additional phase 3 studies, including one focused on cardiovascular outcomes. Wegovy has also recently received label expansions, including for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), which is expected to boost sales.
Manufacturing Challenges and Competition
Despite CagriSema’s promising results, manufacturing complexities and potential costs are concerns. It is expected to be more difficult and expensive to produce than semaglutide, which has previously faced supply constraints. Eli Lilly’s retatrutide, which demonstrated a mean weight loss of up to 28.7% in a phase 3 study, presents a strong competitive challenge.
Is Novo Nordisk a Good Investment?
While Eli Lilly currently appears poised to maintain its lead in the anti-obesity drug market, CagriSema’s superiority to Wegovy and Ozempic should help Novo Nordisk improve its performance, particularly as the company expands its manufacturing capacity. Novo Nordisk also has several other promising diabetes and weight management products in development, including Amycretin, in both oral and subcutaneous formulations.
Frequently Asked Questions (FAQ)
- What is CagriSema?
- CagriSema is an investigational medicine from Novo Nordisk that mimics the actions of two gut hormones, GLP-1 and amylin, to help regulate blood sugar and appetite.
- How does CagriSema compare to Wegovy?
- In a phase 3 trial, CagriSema led to a greater mean weight reduction (22.7%) than Wegovy (16.1%) after 68 weeks.
- What are the potential challenges for Novo Nordisk?
- Manufacturing complexities, higher production costs, and competition from Eli Lilly’s retatrutide are potential challenges.
Don’t miss out! Our analyst team has identified the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. Discover the stocks that could deliver significant returns in the years ahead!
*Stock Advisor returns as of February 16, 2026.
Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Related reading